

Daniel J Wallace

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3593638/publications.pdf>

Version: 2024-02-01

131
papers

13,604
citations

76031

42
h-index

25983

112
g-index

133
all docs

133
docs citations

133
times ranked

11708
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2023, 75, 998-1006.	1.5	7
2	Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. <i>Rheumatology</i> , 2022, 61, 2413-2423.	0.9	25
3	New Insights Into Systemic Lupus Erythematosus Therapies. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e217-e221.	0.5	2
4	Neutrophils Contribute to ER Stress in Lung Epithelial Cells in the Pristane-Induced Diffuse Alveolar Hemorrhage Mouse Model. <i>Frontiers in Immunology</i> , 2022, 13, 790043.	2.2	12
5	Suggested additions to future directions: comment on the <scp>ACR</scp> white paper on antimalarials and cardiac toxicity by Desmarais et al. <i>Arthritis and Rheumatology</i> , 2022, 74, 1300-1301.	2.9	0
6	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1143-1150.	0.5	9
7	Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2022, 74, 1822-1828.	1.5	9
8	Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial. <i>Arthritis Research and Therapy</i> , 2022, 24, 112.	1.6	19
9	Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE). <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 954-955.	0.5	11
10	A Panel of Biomarkers Associates With Increased Risk for Cardiovascular Events in Women With Systemic Lupus Erythematosus. <i>ACR Open Rheumatology</i> , 2021, 3, 209-220.	0.9	14
11	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.5	37
12	A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus. <i>ACR Open Rheumatology</i> , 2021, 3, 116-123.	0.9	5
13	Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 5379-5389.	0.9	11
14	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. <i>Rheumatology</i> , 2021, 60, 4737-4747.	0.9	14
15	COVID-19 in patients with rheumatic disease: finally, a denominator. <i>Lancet Rheumatology</i> , The, 2021, 3, e462-e463.	2.2	1
16	Does hydroxychloroquine improve patient reported outcomes in patients with lupus?. <i>Lupus</i> , 2021, 30, 1790-1798.	0.8	1
17	Innovative Trials and New Opportunities in SLE. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, 481-499.	0.8	2
18	1501-Genetics of age at systemic lupus erythematosus diagnosis. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
19	801â€¦Factors associated with SLE flares after HCQ taper, discontinuation or maintenance in the SLICC inception cohort: lower education linked with higher flare risk. , 2021, , .		0
20	Regulation of cGAS-STING pathway - Implications for systemic lupus erythematosus. Rheumatology and Immunology Research, 2021, 2, 173-184.	0.2	6
21	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Science and Medicine, 2021, 8, e000590.	1.1	31
22	Fiveâ€¦Year Followâ€¦Up of Coronary Microvascular Dysfunction and Coronary Artery Disease in Systemic Lupus Erythematosus: Results From a Communityâ€¦Based Lupus Cohort. Arthritis Care and Research, 2020, 72, 882-887.	1.5	21
23	American Indians Have a Higher Risk of SjÃ¶gren's Syndrome and More Disease Activity Than European Americans and African Americans. Arthritis Care and Research, 2020, 72, 1049-1056.	1.5	14
24	Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatologyâ€¦Classified Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2020, 72, 78-88.	2.9	33
25	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2020, 72, 67-77.	2.9	39
26	Unique SjÃ¶grenâ€¦TM's syndrome patient subsets defined by molecular features. Rheumatology, 2020, 59, 860-868.	0.9	41
27	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2020, 72, 1800-1808.	1.5	23
28	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis and Rheumatology, 2020, 72, 658-666.	2.9	26
29	Raynaudâ€¦TM's Phenomenon From PD-1 Immune Checkpoint Inhibition. JCO Oncology Practice, 2020, 16, 701-702.	1.4	2
30	Oxidative DNA Damage Accelerates Skin Inflammation in Pristane-Induced Lupus Model. Frontiers in Immunology, 2020, 11, 554725.	2.2	32
31	Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. Lupus Science and Medicine, 2020, 7, e000424.	1.1	35
32	O8â€¦Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease. , 2020, , .		0
33	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. Arthritis and Rheumatology, 2020, 72, 1734-1740.	2.9	17
34	Cell-bound complement activation products associate with lupus severity in SLE. Lupus Science and Medicine, 2020, 7, e000377.	1.1	7
35	Attainment of treat-to-target endpoints in SLE patients with high disease activity in the ataccept phase 2b ADDRESS II study. Rheumatology, 2020, 59, 2930-2938.	0.9	33
36	Antinuclear Antibodyâ€¦Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care and Research, 2019, 71, 893-902.	1.5	70

#	ARTICLE	IF	CITATIONS
37	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.5	759
38	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	2.9	1,098
39	Baricitinib for systemic lupus erythematosus – Authors' reply. <i>Lancet, The</i> , 2019, 393, 402-403.	6.3	5
40	Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1235-1241.	0.5	64
41	Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America. <i>Lupus Science and Medicine</i> , 2019, 6, e000317.	1.1	14
42	Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1125-1134.	2.9	74
43	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , 2019, 58, 1259-1267.	0.9	8
44	199 – Baricitinib in patients with systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study. , 2019, , .		2
45	212 – Phase 2, randomized, double-blind, placebo-controlled, dose-finding study, evaluating the Bruton's tyrosine kinase inhibitor evobrutinib in patients with systemic lupus erythematosus: study design. , 2019, , .		2
46	237 – Cell bound complement activation products in combination with low complement C3 or C4 have high diagnostic yield in systemic lupus erythematosus. , 2019, , .		0
47	Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE. <i>Lupus Science and Medicine</i> , 2019, 6, e000349.	1.1	9
48	Drivers of Satisfaction With Care for Patients With Lupus. <i>ACR Open Rheumatology</i> , 2019, 1, 649-656.	0.9	9
49	A Bayesian gene network reveals insight into the JAK-STAT pathway in systemic lupus erythematosus. <i>PLoS ONE</i> , 2019, 14, e0225651.	1.1	8
50	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1010-1012.	0.5	12
51	Clinical Trials in Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 79-85.	0.8	0
52	Best Practices and Challenges to the Practice of Rheumatologists. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, xv-xvi.	0.8	0
53	Mock Recruitment for the Study of Antimalarials in an Incomplete Lupus Erythematosus Trial. <i>Arthritis Care and Research</i> , 2019, 71, 1425-1429.	1.5	2
54	Sex Differences in Quality of Life in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2019, 71, 1647-1652.	1.5	21

#	ARTICLE	IF	CITATIONS
55	A promising approach to targeting type 1 IFN in systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2019, 129, 958-961.	3.9	18
56	Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2018, 5, e000247.	1.1	16
57	A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. <i>Human Molecular Genetics</i> , 2018, 27, 2392-2404.	1.4	34
58	Clinical Efficacy and Safety of Baminercept, a Lymphotoxin Î² Receptor Fusion Protein, in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2018, 70, 1470-1480.	2.9	56
59	Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2018, 70, 868-877.	2.9	63
60	Editorial: Epratuzumab: Reveille or Requiem? Teachable Moments for Lupus and Sjögren's Syndrome Clinical Trials. <i>Arthritis and Rheumatology</i> , 2018, 70, 633-636.	2.9	7
61	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , 2018, 57, 677-687.	0.9	37
62	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1478-1487.	1.5	55
63	Role of psychosocial reserve capacity in anxiety and depression in patients with systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 850-858.	0.9	14
64	Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2018, 70, 266-276.	2.9	184
65	Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 694.	0.7	25
66	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet</i> , The, 2018, 392, 222-231.	6.3	396
67	Serologic features of cohorts with variable genetic risk for systemic lupus erythematosus. <i>Molecular Medicine</i> , 2018, 24, 24.	1.9	12
68	Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. <i>Human Molecular Genetics</i> , 2018, 27, 3813-3824.	1.4	43
69	IL-16/miR-125a axis controls neutrophil recruitment in pristane-induced lung inflammation. <i>JCI Insight</i> , 2018, 3, .	2.3	34
70	Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 534-542.	0.5	111
71	Prevalence of resting-ECG abnormalities in systemic lupus erythematosus: a single-center experience. <i>Clinical Rheumatology</i> , 2017, 36, 1311-1316.	1.0	27
72	Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 153-158.	0.5	40

#	ARTICLE	IF	CITATIONS
73	MicroRNA-302d targets IRF9 to regulate the IFN-induced gene expression in SLE. <i>Journal of Autoimmunity</i> , 2017, 79, 105-111.	3.0	66
74	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , 2017, 8, 16021.	5.8	314
75	Brief Report: Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2017, 69, 2187-2192.	2.9	35
76	Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-blind, Placebo-controlled Trials. <i>Arthritis and Rheumatology</i> , 2017, 69, 362-375.	2.9	189
77	Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features. <i>Arthritis and Rheumatology</i> , 2017, 69, 630-642.	2.9	56
78	Effect of Tobacco Smoking on The Clinical, Histopathological, and Serological Manifestations of Sjögren's Syndrome. <i>PLoS ONE</i> , 2017, 12, e0170249.	1.1	25
79	Identification of a Sjögren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons. <i>PLoS Genetics</i> , 2017, 13, e1006820.	1.5	60
80	X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2016, 68, 1290-1300.	2.9	114
81	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , 2016, 68, 1932-1944.	2.9	40
82	Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products. <i>Lupus Science and Medicine</i> , 2016, 3, e000127.	1.1	24
83	Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome. <i>Clinical Immunology</i> , 2016, 168, 25-29.	1.4	68
84	Cumulative Corticosteroid Dose Over Fifty-two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials. <i>Arthritis and Rheumatology</i> , 2016, 68, 2184-2192.	2.9	44
85	Previous diagnosis of Sjögren's Syndrome as rheumatoid arthritis or systemic lupus erythematosus. <i>Rheumatology</i> , 2016, 55, 1195-1201.	0.9	42
86	Longitudinal Treatment Patterns and Associated Outcomes in Patients With Newly Diagnosed Systemic Lupus Erythematosus. <i>Clinical Therapeutics</i> , 2016, 38, 610-624.	1.1	38
87	Chest pain in lupus patients: the emergency department experience. <i>Clinical Rheumatology</i> , 2015, 34, 1969-1973.	1.0	2
88	Monoclonal Antibodies, Systemic Lupus Erythematosus, and Pregnancy: Insights from an Open-label Study. <i>Journal of Rheumatology</i> , 2015, 42, 728-730.	1.0	8
89	Belimumab: Where Are We Three Years After FDA Approval?. <i>Current Treatment Options in Rheumatology</i> , 2015, 1, 42-50.	0.6	0
90	The evolution of drug discovery in systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2015, 11, 616-620.	3.5	52

#	ARTICLE	IF	CITATIONS
91	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1837-1847.	2.9	98
92	Treatment of systemic lupus erythematosus patients with the BAFF antagonist <i>â€œ</i> ceptibody <i>â€œ</i> blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. <i>Arthritis Research and Therapy</i> , 2015, 17, 215.	1.6	48
93	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1706-1713.	0.5	391
94	Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 183-190.	0.5	266
95	Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SLO006. <i>Rheumatology</i> , 2014, 53, 502-511.	0.9	64
96	A Panel of Biomarkers Is Associated With Increased Risk of the Presence and Progression of Atherosclerosis in Women With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2014, 66, 130-139.	2.9	103
97	Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2014, 41, 300-309.	1.0	149
98	Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. <i>Blood</i> , 2013, 122, 3020-3029.	0.6	98
99	Ten Developments in the Use of Biologicals for Systemic Lupus Erythematosus. <i>Current Rheumatology Reports</i> , 2013, 15, 337.	2.1	1
100	Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. <i>Rheumatology</i> , 2013, 52, 1313-1322.	0.9	115
101	Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 3364-3373.	6.7	100
102	Disease-Specific Patient Reported Outcome Tools for Systemic Lupus Erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 56-65.	1.6	118
103	New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. <i>Nature Reviews Rheumatology</i> , 2012, 8, 522-533.	3.5	176
104	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 2677-2686.	6.7	3,838
105	A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011, 63, 3918-3930.	6.7	1,277
106	High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1619-1624.	0.5	128
107	Advances in drug therapy for systemic lupus erythematosus. <i>BMC Medicine</i> , 2010, 8, 77.	2.3	37
108	Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009, 60, 2428-2437.	6.7	178

#	ARTICLE	IF	CITATIONS
109	Novel evidenceâ€based systemic lupus erythematosus responder index. <i>Arthritis and Rheumatism</i> , 2009, 61, 1143-1151.	6.7	397
110	A phase II, randomized, doubleâ€blind, placeboâ€controlled, doseâ€ranging study of belimumab in patients with active systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009, 61, 1168-1178.	6.7	515
111	Hypothesis: Bipolar Illness with Complaints of Chronic Musculoskeletal Pain Is a Form of Pseudofibromyalgia. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 37, 256-259.	1.6	18
112	Are there models for predicting accelerated atherogenesis in systemic lupus erythematosus?. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 450-451.	3.2	1
113	Editorial [Why is Current Rheumatology Reviews Different that Other Rheumatology Journals?]. <i>Current Rheumatology Reviews</i> , 2007, 3, 171-171.	0.4	0
114	What??s New in the Management of Lupus Since 2000?. <i>Journal of Clinical Rheumatology</i> , 2006, 12, 307-313.	0.5	4
115	New methods for antinuclear antibody testing: does it cut costs and corners without jeopardizing clinical reliability?. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 410-411.	3.2	2
116	Is mycophenolate mofetil a safe and effective treatment for patients with systemic lupus erythematosus?. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 16-17.	3.2	1
117	The physician Hans Reiter as prisoner of war in Nuremberg: A contextual review of his interrogations (1945â€1947). <i>Seminars in Arthritis and Rheumatism</i> , 2003, 32, 208-230.	1.6	30
118	Systemic lupus erythematosus. <i>Drugs of Today</i> , 2002, 38, 259.	2.4	4
119	What constitutes a fibromyalgia expert?. <i>Arthritis and Rheumatism</i> , 1999, 12, 82-84.	6.7	2
120	Leukocytapheresis and rheumatoid arthritis: Comment on the article by Hidaka et al. <i>Arthritis and Rheumatism</i> , 1999, 42, 2255-2255.	6.7	0
121	The Fibromyalgia Syndrome. <i>Annals of Medicine</i> , 1997, 29, 9-21.	1.5	92
122	Prevalence of fibromyalgia in systemic lupus erythematosus patients: comment on the article by Middleton et al. <i>Arthritis and Rheumatism</i> , 1995, 38, 872-872.	6.7	4
123	The Relevance of Antimalarial Therapy with Regard to Thrombosis, Hypercholesterolemia and Cytokines in SLE. <i>Lupus</i> , 1993, 2, 13-15.	0.8	86
124	Inhibition of Protein-Kinase C in Peripheral Blood Mononuclear Cells of Patients with Systemic Lupus Erythematosus: Effect on Spontaneous Immunoglobulin Production. <i>Autoimmunity</i> , 1991, 10, 227-231.	1.2	2
125	Use of autologous pregnancy plasma to treat a flare of juvenile rheumatoid arthritis: Case report and literature review. <i>Journal of Clinical Apheresis</i> , 1987, 3, 216-218.	0.7	3
126	Thirty-four-year delayed-onset lupus nephritis: a case report. <i>Arthritis and Rheumatism</i> , 1987, 30, 479-480.	6.7	10

#	ARTICLE	IF	CITATIONS
127	Combination immunosuppressive treatment of steroid-resistant dermatomyositis/polymyositis. <i>Arthritis and Rheumatism</i> , 1985, 28, 590-592.	6.7	46
128	Plasmapheresis versus lymphoplasmapheresis in rheumatoid arthritis: Immunologic comparisons and literature review. <i>Journal of Clinical Apheresis</i> , 1984, 2, 184-189.	0.7	9
129	Severe giant cell valvulitis in a patient with reiter's syndrome. <i>Arthritis and Rheumatism</i> , 1982, 25, 232-234.	6.7	9
130	Plasmapheresis and lymphoplasmapheresis in the management of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1979, 22, 703-710.	6.7	130
131	The Biology of Aging: 1976, An Overview. <i>Journal of the American Geriatrics Society</i> , 1977, 25, 104-111.	1.3	8